Vidaza

DRUG5 trials

Sponsors

Ohio State University Comprehensive Cancer Center, University of Oklahoma, University of Miami, MedImmune LLC, Celgene

Conditions

Acute Myeloid LeukemiaBreast CancerGenitourinaryGlioblastoma MultiformeHematological NeoplasmsHodgkin's LymphomaHypermethylationLeukemia

Phase 1

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

CompletedNCT00624936

Ohio State University Comprehensive Cancer CenterLeukemia, Myelodysplastic/Myeloproliferative Neoplasms, Myelodysplastic Syndromes

Start: 2008-04-30End: 2014-06-30Updated: 2017-08-22

Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

TerminatedNCT01167816

University of OklahomaPancreatic Cancer

Start: 2010-07-31End: 2014-01-31Updated: 2014-05-20

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

CompletedNCT02117219

MedImmune LLCMyelodysplastic Syndrome

Start: 2014-05-20End: 2019-04-30Updated: 2019-05-10

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

CompletedNCT02223052

CelgeneAcute Myeloid Leukemia, Breast Cancer, Genitourinary +17

Start: 2014-10-27End: 2018-12-18Updated: 2020-05-12

Unknown Phase

Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

CompletedNCT01209520

University of MiamiHypermethylation, Lung Cancer, Non Small Cell Lung Carcinoma

Start: 2009-07-31Updated: 2015-02-24

Related Papers

Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in myelodysplastic syndrome (MDS) after treatment with hypomethylating agents.

Journal of Clinical Oncology2015-05-202 citations